The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
Open accessAbstract
The guideline group was selected to be representative of UK-based medical experts. MEDLINE and EMBASE were searched systematically for publications in English, using the keywords: thrombotic thrombocytopenia purpura (TTP), ADAMTS13, plasma exchange (PEX) and relevant key words related to the subsections of this guideline. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the BCSH. The guideline was then reviewed by a sounding board of British haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The 'GRADE' system was used to quote levels and grades of evidence, details of which can be found at http://www.bcshguidelines.com. The objective of this guideline is to provide healthcare professionals with clear, up-to-date, and practical guidance on the management of TTP and related thrombotic microangiopathies, defined by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA) and small vessel thrombosis. Thrombotic thrombocytopenic purpura (TTP) is rare, with a reported incidence of six cases per million per year in the UK (Scully et al, 2008). It is an important diagnosis to make because the untreated mortality is 90%, which can be reduced with the prompt delivery of plasma exchange (PEX). Early death still occurs: approximately half of the deaths in the regional UK registry occurred within 24 h of presentation, primarily in women (Scully et al, 2008). In the last 15 years there has been a marked increase in the understanding of the pathogenesis of TTP. It is now recognized that congenital and acute acquired TTP are due to a deficiency of von Willebrand factor (VWF) cleaving protein, also known as ADAMTS1, (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 – von Willebrand factor cleaving protein) (Fujikawa et al, 2001; Levy et al, 2001). In the absence of ADAMTS13, ultra large multimers of VWF (ULVWF) released from endothelium are not cleaved appropriately, and cause spontaneous platelet aggregates in conditions of high shear, such as in the microvasculature of the brain, heart and kidneys. Congenital TTP is due to an inherited deficiency of ADAMTS13, but acquired immune TTP is due to the reduction of ADAMTS13 by autoantibodies directed against ADAMTS13 (Furlan et al, 1998a; Tsai & Lian, 1998). Other clinical forms of thrombotic microangiopathy (TMA) occur in the absence of severe deficiency. Diagnosis can be difficult, as there is clinical overlap with haemolytic uraemic syndrome (HUS), autoimmune disease and a spectrum of pregnancy-related problems. Thrombotic thrombocytopenic purpura was originally characterized by a pentad of thrombocytopenia, MAHA, fluctuating neurological signs, renal impairment and fever, often with insidious onset. However, TTP can present without the full pentad; up to 35% of patients do not have neurological signs at presentation and renal abnormalities and fever are not prominent features. The revised diagnostic criteria state that TTP must be considered in the presence of thrombocytopenia and MAHA alone (Galbusera et al, 2006). This can result in an increased referral of other TMAs (Table 1). TTP remains a diagnosis based on clinical history, examination of the patient and the blood film. ADAMTS 13 assays help to confirm the diagnosis and monitor the course of the disease and possible need for additional treatments. Presenting symptoms and signs are summarized in Table 2 and reflect widespread multi organ thromboses. Neurological impairment has multiple presentations including headache, altered personality, reduced cognition, transient ischaemic attacks, fits and fluctuating levels of consciousness including coma; the latter is a poor prognostic sign. Acute renal failure requiring haemodialysis is rare in TTP and more indicative of HUS (Coppo et al, 2006; Scully et al, 2008). Additional ischaemic complications may be seen, such as abdominal pain due to intestinal ischaemia. Consumption of platelets in platelet-rich thrombi results in thrombocytopenia. The median platelet count is typically 10–30 × 109/l at presentation (Dervenoulas et al, 2000; Vesely et al, 2003; Coppo et al, 2006; Tuncer et al, 2007; Scully et al, 2008). Mechanical fragmentation of erythrocytes during flow through partially occluded, high shear small vessels causes a MAHA. Median haemoglobin levels on admission are typically 80–100 g/l, with schistocytes in the film, low haptoglobin levels and raised reticulocyte counts due to haemolysis. The direct Coombs test is negative. The combination of haemolysis and tissue ischaemia produces elevated lactate dehydrogenase (LDH) values. The clotting screen (prothrombin time, activated partial thromboplastin time and fibrinogen) is usually normal. A virology screen pre-treatment is necessary to exclude human immunodeficency virus (HIV) and other viral-associated TTP, and a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., & Yetisir, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400601 · Cited by 5,187
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
(1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401322 · Cited by 2,037
Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., & Spasoff, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250604 · Cited by 1,920
Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
Tsai, H.-M., & Lian, E. C.-Y. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392203 · Cited by 1,760
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
Levy, G. G., Nichols, W. C., Lian, E. C., Foroud, T., McClintick, J. N., McGee, B. M., Yang, A. Y., Siemieniak, D. R., Stark, K. R., Gruppo, R., et al. (2001) · Nature · doi:10.1038/35097008 · Cited by 1,749
Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P. A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392202 · Cited by 1,657
Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant
British Committee for Standards in Haematology, B. T. T. F. (. D., O'Shaughnessy, D. F., Atterbury, C., Bolton Maggs, P., Murphy, M., Thomas, D., Yates, S., & Williamson, L. M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04972.x · Cited by 840
Vesely, S. K., George, J. N., Lämmle, B., Studt, J.-D., Alberio, L., El-Harake, M. A., & Raskob, G. E. (2003) · Blood · doi:10.1182/blood-2003-01-0193 · Cited by 676
Fujikawa, K., Suzuki, H., McMullen, B., & Chung, D. (2001) · Blood · doi:10.1182/blood.v98.6.1662 · Cited by 609
Pregnancy outcomes after maternal exposure to rituximab
Chakravarty, E. F., Murray, E. R., Kelman, A., & Farmer, P. (2011) · Blood · doi:10.1182/blood-2010-07-295444 · Cited by 586
Thrombotic Thrombocytopenic Purpura
(2006) · New England Journal of Medicine · doi:10.1056/nejmc061483 · Cited by 573
Furlan, M., Robles, R., Solenthaler, M., Wassmer, M., Sandoz, P., & Lämmle, B. (1997) · Blood · doi:10.1182/blood.v89.9.3097 · Cited by 541
Eculizumab in Severe Shiga-Toxin–Associated HUS
Lapeyraque, A.-L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., Proulx, F., Clermont, M.-J., Le Deist, F., Niaudet, P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1100859 · Cited by 423
Ruutu, T., Barosi, G., Benjamin, R. J., Clark, R. E., George, J. N., Gratwohl, A., Holler, E., Iacobelli, M., Kentouche, K., Lammle, B., et al. (2007) · Haematologica · doi:10.3324/haematol.10699 · Cited by 395
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias
Allford, S. L., Hunt, B. J., Rose, P., Machin, S. J., & on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04049.x · Cited by 383
Self-citationGuideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
The European Paediatric Study Group for HUS, Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C. M., et al. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-0964-1 · Cited by 352
TERRELL, D. R., WILLIAMS, L. A., VESELY, S. K., LÄMMLE, B., HOVINGA, J. A. K., & GEORGE, J. N. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01436.x · Cited by 334
Furlan, M., Robles, R., Solenthaler, M., & Lämmle, B. (1998) · Blood · doi:10.1182/blood.v91.8.2839.2839_2839_2846 · Cited by 326
Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.-P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., et al. (2007) · Blood · doi:10.1182/blood-2006-02-006064 · Cited by 295
Taylor, C. M., Machin, S., Wigmore, S. J., Goodship, T. H. J., & on behalf of a working party from the Renal Association, T. B. C. F. S. I. H. A. T. B. T. S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07916.x · Cited by 277
Self-citationScully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I., & Machin, S. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06448.x · Cited by 267
Self-citationGeorge, J. N., Li, X., McMinn, J. R., Terrell, D. R., Vesely, S. K., & Selby, G. B. (2004) · Transfusion · doi:10.1111/j.1537-2995.2004.00700.x · Cited by 246
Robles, R., Morselli, B., Sandoz, P., Lämmle, B., & Furlan, M. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614408 · Cited by 218
von Willebrand factor cleaving protease and ADAMTS13mutations in childhood TTP
Schneppenheim, R., Budde, U., Oyen, F., Angerhaus, D., Aumann, V., Drewke, E., Hassenpflug, W., Häberle, J., Kentouche, K., Kohne, E., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2399 · Cited by 217
Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura
Scully, M., Starke, R. D., Lee, R., Mackie, I. J., Machin, S. J., & Cohen, H. (2006) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000240918.65306.20 · Cited by 110
Self-citationMcDonald, V., Manns, K., Mackie, I. J., Machin, S. J., & Scully, M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03818.x · Cited by 109
Self-citationZakarija, A., Kwaan, H. C., Moake, J. L., Bandarenko, N., Pandey, D. K., McKoy, J. M., Yarnold, P. R., Raisch, D. W., Winters, J. L., Raife, T. J., et al. (2009) · Kidney International · doi:10.1038/ki.2008.613 · Cited by 96
Thrombotic microangiopathy and retroviral infections: A 13‐year experience
Ucar, A., Fernandez, H. F., BYRNES, J. J., Lian, E. C. Y., & Harrington, W. J. (1994) · American Journal of Hematology · doi:10.1002/ajh.2830450407 · Cited by 71
Management of cancer‐associated thrombotic microangiopathy: What is the right approach?
Werner, T. L., Agarwal, N., Carney, H. M., et al. (2006) · American Journal of Hematology · doi:10.1002/ajh.20783 · Cited by 65
Thrombotic thrombocytopenic purpura and simvastatin
McCarthy, L. J., Porcu, P., Fausel, C. A., Sweeney, C. J., & Danielson, C. (1998) · The Lancet · doi:10.1016/s0140-6736(05)70492-x · Cited by 51
Incidence and prognosis of acute heart failure in the thrombotic microangiopathies
Gami, A. S., Hayman, S. R., Grande, J. P., & Garovic, V. D. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.019 · Cited by 47
Tuncer, H. H., Oster, R. A., Huang, S. T., & Marques, M. B. (2006) · Transfusion · doi:10.1111/j.1537-2995.2007.01071.x · Cited by 37
Thrombotic thrombocytopenic purpura associated with statin treatment
Sundram, F., Roberts, P., Kennedy, B., & Pavord, S. R. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.017178 · Cited by 25
Simvastatin and thrombotic thrombocytopenic purpura
Koduri, P. R. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61366-9 · Cited by 11
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Scully, M., Cataland, S. R., Peyvandi, F., Coppo, P., Knöbl, P., Kremer Hovinga, J. A., Metjian, A., de la Rubia, J., Pavenski, K., Callewaert, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806311 · Cited by 1,025
Self-citationSchwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Thrombotic thrombocytopenic purpura
Joly, B. S., Coppo, P., & Veyradier, A. (2017) · Blood · doi:10.1182/blood-2016-10-709857 · Cited by 716
Metadata
- Authors
- Scully, M., Hunt, B. J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B., Machin, S. J., & on behalf of British Committee for Standards in Haematology
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2012-05-25
- Volume
- 158
- Issue
- 3
- Pages
- 323-335
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2010802708
- Cited by
- 863
- References
- 34
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.